CME

Faculty: Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP Faculty: Florence Odufalu, MD This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, a...

Faculty: David T. Rubin, MD Faculty: Michael Dolinger, MD, MBA This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulatio...

Faculty: Florence-Damilola Odufalu, MD This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illust...

Faculty: David T. Rubin, MD Faculty: Ugonna Iroku, MD, MHS This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A...

Faculty: Brendon Neuen, MBBS, PhD Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) emphasized the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD. The updated guidance emphasizes proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selecti...

Faculty: April W. Armstrong, MD, MPH Faculty: Melinda Gooderham, MSc, MD, FRCPC There have been exciting advances in the treatment of psoriasis. Join Drs. April Armstrong and Melinda Gooderham for this expert discussion to learn about the most recent data on TKY2 inhibitors, presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado.

Faculty: Prem S. Subramanian, MD, PhD Faculty: Andrew G. Lee, MD Faculty: Valerie Biousse, MD This program addresses critical practice gaps in the evaluation and management of non-arteritic anterior ischemic optic neuropathy (NAION). Faculty will review acute ischemic pathophysiology, diagnostic variability, and structured approaches to improve diagnostic accuracy and readiness for clinical trials...

Faculty: Chee Kay Cheung, MBCHB, MRCP, PHD Faculty: Claudia Seikrit Our experts review updated KDIGO practice guideline recommendations for proteinuria reduction in IgA nephropathy (IgAN) and their implications for clinical care. Drs. Chee Kay Cheung and Claudia Seikrit examine the shift toward lower proteinuria targets (<0.3 g/day) and the rationale for earlier, more intensive intervention, em...

Faculty: Cem Akin, MD, PhD This online CME activity explores the clinical complexity and real-world impact of systemic mastocytosis through both clinician insight and patient experience. Participants will examine the multisystem burden of this disease, challenges in diagnosis, and the importance of recognizing symptoms that are often underestimated. The program reviews current evidence-based and t...

Faculty: Harry Erba, MD, PhD This educational series explores evolving strategies in the management of acute myeloid leukemia (AML) with a focus on targeted therapies. Faculty experts will review molecular diagnostics and guideline-driven use of FLT3 and menin inhibitors across treatment lines, including frontline, relapsed/refractory, and maintenance settings. Participants will examine clinical t...

Faculty: Deepak Sambhara, MD This rebroadcast of a live regional meeting series, part of The Focused Sight Initiative: Quality Improvement Interventions in Retinal Diseases, brings together retina specialists and eye care professionals to address systemic gaps in the timely diagnosis, referral, and management of patients with retinal diseases, including age-related macular degeneration (AMD), diab...

Faculty: John E. Anderson, MD Faculty: Davida F. Kruger, CNP Continuous glucose monitoring (CGM) has been widely used in individuals with type 1 diabetes (T1D), and evolving guidelines increasingly recommend its use for those with type 2 diabetes (T2D) as well. However, despite these updated recommendations, real-world adoption to support T2D management has remained lower than expected. Before exp...

Faculty: Richard Lafayette, MD, FACP Faculty: Ankana Daga, MD Complement-mediated kidney diseases such as C3 glomerulopathy (C3G) continue to present significant diagnostic and therapeutic challenges in nephrology for both adult and pediatric patients. Among children, this rare disease can progress to end-stage kidney disease within 10 years of diagnosis. Traditional treatment options include supp...

Faculty: Ravindra Uppaluri, MD, PhD Faculty: Nancy Lee, MD, FASTRO This activity reviews data from the KEYNOTE-689 and NIVOPOSTOP trials evaluating perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Experts examine trial design, efficacy outcomes, and the role of PD-L1 combined positive score (CPS) in patient selection. Drs. Up...

Faculty: Mariana C. Castells, MD, PhD Faculty: Tsewang Tashi, MD This online educational activity explores the evolving role of KIT-targeted tyrosine kinase inhibitors (TKIs) in indolent systemic mastocytosis (ISM). Expert faculty discuss pivotal clinical data supporting the approval of avapritinib, a potent TKI that targets KIT D816V, in patients with ISM. They also highlight emerging clinical ev...

Faculty: Antoine Lanot, MD, PhD Faculty: Gil Yosipovitch, MD Despite effective and recommended therapies, many healthcare providers still consider antihistamines as the first-choice treatment for CKD-associated pruritus. Join Drs. Antoine Lanot and Gil Yosipovitch as they review a clinical patient case from a multidisciplinary perspective and consider best practices for the diagnosis, treatment, a...

Faculty: Anjali Owens, MD Faculty: Ahmad Masri, MD, MS This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharm...

Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynam...

Faculty: Ahmad Masri, MD, MS Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharm...

Faculty: Michael Nassif, MD, MSc Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, p...

Faculty: Michael Nassif, MD, MSc Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, p...

Faculty: Ahmad Masri, MD, MS Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharm...

Faculty: Ahmad Masri, MD, MS Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharm...

Faculty: Michael Nassif, MD, MSc This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharma...

Faculty: Maria Pabon, MD Faculty: Robert J. Mentz, MD, FHFSA, FACC In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They contrast steroidal and nonsteroidal MRAs, highlighting differences in receptor selectivity, c...